Background. Recent studies suggest that infection with human T-lymphotropic virus 1 (HTLV-1) might be associated with bronchiectasis among Indigenous Australians. The present study compared the clinical characteristics and outcomes of bronchiectasis in this population, according to HTLV-1 serologic status.
Bronchiectasis is characterized by the pathologic dilatation of bronchi [1] , leading to impaired drainage of secretions and bacterial colonization of the respiratory tract [1] . In the preantibiotic era, pneumonia and complications, including cor pulmonale and hemoptysis, resulted in considerable morbidity and early mortality [1] . More recently, prevalence rates have fallen markedly in developed countries, complications are uncommon, and life expectancy has increased substantially [1, 2] . Nevertheless, bronchiectasis remains a major cause of morbidity and premature death among the Indigenous populations of affluent countries. At least 1.5% of Indigenous children in Alaska [3] and central Australia [4] , for example, require admission for the management of bronchiectasis, and 13% of Indigenous Australian adults with bronchiectasis died during a single year of follow-up in a recent study [5] .
The reason for such a high prevalence of bronchiectasis among the Indigenous people of central Australia remains unclear. Tuberculosis, measles, and pertussis, common etiologic agents in developing countries, are uncommon, and causes that are more prevalent in developed countries, such as cystic fibrosis, have not been reported [6, 7] . Bronchiectasis has therefore been attributed to recurrent pneumonia resulting from overcrowded housing, barriers to personal hygiene, and exposure to smoke from biocombustion [7] . However, incidence rates among Indigenous children in central Australia are more than twice the rates among those in the far north of the Northern Territory [8] , and another undefined etiologic factor has been proposed that contributes to respiratory diseases, including bronchiectasis, in central Australia [7] .
Recently, we reported an association between human T-lymphotropic virus 1 (HTLV-1) infection and bronchiectasis [5] . In a retrospective review of patients admitted to Alice Springs Hospital (ASH), 18 (72%) of 25 patients tested were HTLV-1 seropositive, compared with background prevalence rates between 7.2% [9] and 13.9% [10] . HTLV-1 is an RNA virus of the genus Deltaretrovirus that infects as many as 20 million persons worldwide [11] . In Australia, the virus is prevalent among the Indigenous population of central Australia, but it is rare elsewhere [10] . The major recognized complications of HTLV-1 infection are adult T-cell leukemia/lymphoma [12] and inflammatory disorders, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [12, 13] . Pulmonary inflammation [13] [14] [15] [16] has been reported in these patients [13] [14] [15] [17] [18] [19] [20] [21] , and subclinical bronchiectasis has been recognized among asymptomatic HTLV-1 carriers in Japan [22] . The present study was commenced to determine whether HTLV-1 infection alters clinical presentations or outcomes of bronchiectasis among socioeconomically disadvantaged Indigenous adults residing in central Australia.
METHODS

Study Setting and Design
The study setting, ASH, is a 165-bed community-based hospital with limited diagnostic and treatment facilities. The closest tertiary referral centers are in Darwin and Adelaide, Australia, both .1500 km away. ASH is the only facility serving an arid region of .1 000 000 km 2 that is sparsely populated by 47 000
persons. Indigenous Australians make up .40% of the regional population and 70% of all medical inpatients at ASH. Adult patients with a discharge diagnosis of bronchiectasis were identified from the ASH patient information database for the period 1 January 2000 through 31 December 2006. A retrospective review of medical records was then performed for Indigenous patients if (1) bronchiectasis had been diagnosed radiologically according to American College of Chest Physicians guidelines [23] and (2) their HTLV-1 serostatus was known. All admissions from childhood to study end or death were examined in detail. Information for each admission, including demographic characteristics, particulars of the clinical presentation, radiologic findings, microbiologic findings, and outcome, were abstracted using a standardized data collection form. Results of more-specialized tests, such as spirometry, echocardiography, or other tests to determine etiology, were recorded when these were performed.
The ASH microbiology laboratory has a limited bacteriologic capability. Other tests, including mycobacteriologic analyses, are sent to specialized laboratories outside the Northern Territory. Nontuberculous mycobacteria were identified to the species level only if isolated on $2 occasions. Data are included for patients who had any positive result of sputum culture or $3 cultures of sputum samples negative for mycobacteria. HTLV-1 serology was performed at the National Reference Laboratory (Melbourne, Australia). Samples were initially screened using both the Serodia HTLV-1 particle agglutination assay (Fujirebio) and the Murex HTLV-I1II test kit (Murex Diagnostics). HTLV-1 serostatus was then confirmed by Western blot analysis (HTLV Blot 2.4; MP Diagnostics), using stringent criteria. Samples were considered seropositive if reactive to env (gp46) or to both recombinant envelope proteins (Rgp21 and Rgp46I) and $3 other viral specific proteins of the gag or pol series. No patients were tested in childhood.
Residence .100 km from Alice Springs was defined as remote. Pneumonia was defined as presentation with an acute lower respiratory tract infection with radiologic evidence of consolidation and was further categorized as bronchopneumonia or lobar pneumonia. The number of lobes affected by bronchiectasis, as well as the presence of cystic bronchiectasis, ground-glass opacities, and emphysematous changes, were included only for those patients who underwent chest high-resolution computed tomography (HRCT). Results of all imaging were recorded from reports written by a consultant radiologist.
All-cause mortality rates were determined from data provided to ASH by the Northern Territory Registry for Births, Deaths, and Marriages. Out-of-hospital deaths were not included in the analysis of specific causes of deaths, which were determined by reviewing case notes. The study was approved by the Central Australian Human Research Ethics Committee.
Statistics
Prevalence was determined using the number of individuals with radiologically confirmed bronchiectasis admitted during the study period, divided by the population of Indigenous adults The v 2 test and, in the case of small numbers, the Fisher exact test were used to analyze categorical variables. Continuous variables were assessed for skew, with normally distributed variables analyzed using the t test and nonnormal variables analyzed using the Wilcoxon rank sum test. Logistic regression was used to assess for predictors of HTLV-1 infection, bronchiectasisrelated mortality, and overall mortality. Univariable logistic regression was used to identify candidate predictors for the multivariable models. Final multivariable models were derived through a process of backward elimination in which nonsignificant predictors were sequentially removed from the model, leaving a subset of wholly significant predictors. A postestimation Hosmer and Lemeshow test was applied to assess goodness of fit of the final models. In all analyses, differences were considered significant at P , .05. All statistical analysis was performed using Stata software, version 11 (Stata). The follow-up period ended on 30 June 2007.
RESULTS
One hundred twenty Indigenous and 2 non-Indigenous resident adults were admitted with bronchiectasis during the study period. Prevalence rates were 103/10 000 and 1.01/10 000 population for Indigenous and non-Indigenous adults, respectively. 
Childhood Presentations
Demographic characteristics and clinical presentations in childhood are presented in Table 1 . Fifty patients (56.2% of the adult cohort) first presented in childhood ( Table 1) . As children, HTLV-1-seropositive subjects had a higher median number of lobes affected by each episode of pneumonia (P 5 .028) but were less likely to have an episode of lobar pneumonia (univariable OR, 0.11; 95% CI, .02-.52; P 5 .005) or to have a cause found (univariable OR, 0.24; 95% CI, .06-.99; P 5 .049) ( Table 1 ). Only HTLV-1-seropositive adults were admitted in childhood specifically for the treatment of an infected skin condition (5/31 [16.1%]; P 5 .142) ( Table 1) .
Adult Presentations
Demographic characteristics, comorbidities, and complications arising in adulthood are presented in Table 2 . Excluding patients who received a diagnosis of bronchiectasis during their first admission, 90% of patients in both groups were previously admitted with pneumonia (HTLV-1-seropositive group, 40/44; HTLV-1-seronegative group, 25/28). No other etiologic factor was found among 30 patients who underwent further investigations, including measurement of immunoglobulin levels, human immunodeficiency virus serology, autoimmune antibody tests, and tests for Aspergillus precipitins. HTLV-1-seropositive patients were significantly more likely to have d Causes identified before diagnosis with bronchiectasis: HTLV-1-seropositive adults, Haemophilus influenzae (n 5 5), Streptococcus pneumoniae (n 5 4), and complicated strongyloidiasis (n 5 1); HTLV-1-seronegative adults, S. pneumoniae (n 5 7), H. influenzae (n 5 6), complicated strongyloidiasis (n 5 2), adenovirus (n 5 1), measles (n 5 1), and aspiration (n 5 4). e Among patients presenting with a respiratory infection in childhood.
scabies infestation (P 5 .041) and to have been admitted specifically for the treatment of an infected skin condition (P 5 .019) ( Table 2) .
Radiologic Findings
Before diagnosis with bronchiectasis, more lobes were affected by pneumonia for a given number of episodes among e Age at first respiratory presentation in adulthood.
f Excluding patients with bronchiectasis diagnosed in childhood.
g After diagnosis with bronchiectasis.
h Admitted with scabies, skin infections, or strongyloidiasis at any age.
i Among patients tested for strongyloidiasis serologically.
j Excluding patients with rheumatic heart disease (1 HTLV-1-seropositive and 2 HTLV-1-seronegative patients) or dilated cardiomyopathy (1 HTLV-1-seronegative patient).
HTLV-1-seropositive adults, suggesting that recurrent pneumonia was more likely to involve different lobes in this group (Table 2) . After diagnosis, the median numbers of bronchiectatic lobes did not differ significantly between groups (P 5 .063); however, bronchiectasis was more likely to be bilateral in HTLV-1-seropositive adults (HTLV-1-seropositive group, 72.5%; HTLV-1-seronegative group, 50%; P 5 .032) ( 
Microbiologic Findings
Three hundred eighty-nine bacterial pathogens (HTLV-1-seropositive group, 239; HTLV-1-seronegative group, 150) were isolated from 1825 cultures of respiratory specimens performed during infective exacerbations of bronchiectasis. Among sputum cultures yielding a pathogen, there were no differences between groups in the proportion of pathogens isolated. These included Haemophilus influenzae (48.8% of patients), Streptococcus pneumoniae (22.4%), Pseudomonas aeruginosa (12.3%), enteric organisms (6.4%), and Staphylococcus aureus (5.4%). However, after correction for the number of sputum specimens cultured, HTLV-1-seropositive patients were less likely to have a pathogen isolated during an infective exacerbation (P 5 .042) ( Table 2 ). For each unit increase in the number of pathogens cultured from sputum, the odds of HTLV-1 infection was reduced by 95% (univariable OR, 0.05; 95% CI, .00-.44; P 5 .007). In contrast, mycobacteria were isolated from 18 (50.0%) of 36 HTLV-1-seropositive patients and 5 (27.8%) of 18 HTLV-1-seronegative patients (P 5 .125).
Most frequently identified to the species level were Mycobacterium avium intracellulare complex (HTLV-1-seropositive group, 6; HTLV-1-seronegative group, 1) and Mycobacterium tuberculosis (HTLV-1-seropositive group, 3; HTLV-1-seronegative group, 0).
Outcomes HTLV-1-seropositive adults were more likely to have a clinical diagnosis of cor pulmonale (P 5 .023) and echocardiographic findings consistent with elevated pulmonary arterial pressures (Table 2) . HTLV-1-seropositive patients were also more likely to have a clinical diagnosis of congestive cardiac failure (P 5 .013). Other complications did not differ between groups (Table 2) . HTLV-1-seropositive patients were significantly more likely to die from a bronchiectasis-related complication (OR, 5.78; 95% CI, 1.17-26.75; P 5 .028) ( Table 3 ). Among HTLV-1-seropositive patients, causes of death included pneumonia (11 patients), respiratory failure (1 patient), and hemoptysis (1 patient). The deaths of both HTLV-1-seronegative patients were the result of pneumonia. The mean ages at death (6 standard error) were 44.5 6 2.9 years and 41.2 6 8.7 years for HTLV-1-seropositive and HTLV-1-seronegative patients, respectively (P 5 .495). Univariable predictors of a bronchiectasisrelated death included HTLV-1 seropositivity, cor pulmonale, empyema/pulmonary abscesses, isolation of P. aeruginosa from sputum during an infective exacerbation, emphysematous changes at chest HRCT, scabies infestation, and a previous admission for treatment of infected skin lesions (Table 3) . No multivariable model specific for bronchiectasis-related deaths could be derived. However, being admitted for treatment of infected skin lesions (OR, 6.77; 95% CI, 1.46-31.34; P 5 .014) and chronic respiratory failure (OR, 4.65; 95% CI, 1.63-13.28; P 5 .004) were predictive of death in a multivariable model of all-cause mortality.
DISCUSSION
Indigenous Australians have among the highest prevalence rates of bronchiectasis and the worst outcomes reported worldwide. More than 1.0% of all Indigenous adults residing in central Australia were hospitalized with bronchiectasis during the study. These rates contrast sharply with those in other developed countries, where prevalence has progressively fallen from 13.0/ 10 000 population in the 1950s [24] to 5.2/10 000 population this century [25] . In our study population, bronchiectasis was associated with a very high mortality rate; 34.2% of our cohort died during the study period, at a median age of 42.5 years.
Elsewhere in Australia, the median age of presentation for nonIndigenous adults with bronchiectasis now approaches 60 years [26] , and the mean age at death among these patients has risen to 73 years [2] . Falling prevalence rates of bronchiectasis in developed countries have been attributed to vaccination against childhood respiratory diseases, improved treatment of bacterial infections in childhood, and control of tuberculosis [1] . Idiopathic disease predominates in this setting, and $60% of cases are now women [26] . In contrast, 90% of Indigenous patients in the present study were previously admitted with pneumonia, and males were most frequently affected. Among Indigenous Australians, measles, pertussis, and tuberculosis are rare; cystic fibrosis has not been reported [6, 7] ; and hypogammaglobulinemia is uncommon [6, 7] . A further etiologic factor has therefore been proposed to account for the absence of an increased risk of bronchiectasis following lobar pneumonia, compared with bronchopneumonia [7] .
The present study suggests that HTLV-1 infection contributes substantially to the risk of developing bronchiectasis in Indigenous Australians. Among 89 patients whose serologic status could be determined, nearly 60% were HTLV-1 seropositive, 5 times historical background prevalence rates (7.2%-13.9%) [9, 10] . HTLV-1 infection was also associated with differences in childhood presentations and adult outcomes. HTLV-1-seropositive adults were more likely to present in childhood with multilobar pulmonary infiltrates but were less likely than HTLV-1-seronegative children to have lobar consolidation or to have a cause of pneumonia found. In adulthood, HTLV-1-seropositive adults had more extensive bronchiectasis and were more likely to have ground-glass opacities present at chest HRCT, yet the likelihood of isolating a pathogen during an infective exacerbation was reduced. HTLV-1-seropositive adults were also more likely to have both clinical and echocardiographic evidence of pulmonary hypertension, and the risk of bronchiectasis-related death was increased nearly 6-fold. Admissions for infected skin lesions were more frequent among HTLV-1-infected patients, and this predicted death at multivariable analysis. An association between infected skin lesions and bronchiectasis has previously been described among HTLV-1 carriers with infective dermatitis in Jamaica [27] .
HTLV-1 infection is associated with several inflammatory conditions, including HAM/TSP [12] and uveitis [12] . Pulmonary involvement has been reported in these patients [13] [14] [15] [16] and in otherwise healthy carriers [19] [20] [21] . The proportion of lymphocytes [13-15, 17, 19, 21] , which are frequently HTLV-1 infected [18, 28, 29] and have very high HTLV-1 proviral loads [21] , is increased among cells obtained by bronchoalveolar lavage. The presence of infected lymphocytes in bronchoalveolar lavage fluid is associated with increased HTLV-1 tax/rex mRNA expression in vivo [28] . A high HTLV-1 proviral load [12] and the expression of the immunodominant viral antigen, Tax [30] , are thought to be risk factors for the development of HTLV-1-related inflammatory disorders involving other tissues [12, 30] . The pathologic correlate of these observations is a lymphocytic infiltration of bronchiole walls and mucosal glands [16] , which may lead to insufficiency of respiratory tract mucus [16] .
Radiologic evidence of pulmonary involvement has been reported in 50% of patients with HAM/TSP [29] and in 30% of asymptomatic carriers, of whom 18% have subclinical bronchiectasis [22] . Nevertheless, even when lymphocyte infiltration [13] and viral expression [20, 21] can be demonstrated, symptomatic pulmonary disease is uncommon elsewhere [31] [32] [33] . Clinical manifestations of HTLV-1-associated pulmonary disease therefore appear to be determined by other etiologic factors, which might influence HTLV-1 proviral load and the inflammatory response to proviral expression. The major determinant of the HTLV-1 proviral load are genetic differences that determine the efficiency with which cytotoxic T lymphocytes destroy infected cells [34] . However, tax expression and inflammatory disease are also associated with HTLV-1 proviral integration into transcriptionally active regions [34] . HTLV-1 proviral load might therefore be driven by T-cell activation resulting from repeated or persistent infections with pathogens other than HTLV-1 [34] . This suggests that socioeconomic factors might contribute to regional differences in the pulmonary manifestations of HTLV-1 infection. In contrast to the housing of HTLV-1 carriers in other developed countries, housing in Indigenous communities is typically overcrowded [35] , poorly maintained [35] , and offers little opportunity to attend to personal hygiene [36] . In this setting, recurrent bacterial and parasitic infections [37, 38] may both increase HTLV-1 proviral load and more directly lead to pulmonary parenchymal damage and disease progression.
The retrospective nature of the present study resulted in a number of limitations. Not all patients were tested for HTLV-1, raising the possibility of selection bias. However, HTLV-1 serology was performed for 92 (76.7%) of 120 patients, and even if all 28 untested patients were HTLV-1 seronegative, the proportion of HTLV-1-seropositive patients (43.3%) would remain far higher than background rates. We were also unable to determine whether patients who were HTLV-1 seropositive in adulthood were infected in childhood. Nevertheless, prolonged breast-feeding is likely to be the primary route of HTLV-1 transmission in central Australia [38] , and infection with HTLV-1 in early childhood could explain differences in childhood respiratory presentations between HTLV-1-seropositive and HTLV-1-seronegative groups. Although investigations to exclude other causes of bronchiectasis were not performed for most patients, previous studies have excluded cystic fibrosis and hypogammaglobulinemia in .90% of cases of childhood bronchiectasis in our study population [4, 7] . Finally, the use of a hospital-based cohort excludes less severe cases that might be successfully managed outside the hospital, and our results may not be applicable in a community-based setting.
HTLV-1 infects the poorest members of society worldwide [11] , and this includes Indigenous Australians, among whom no attempt has been made to control viral transmission. Indigenous Australians also have among the highest reported rates of bronchiectasis, which undoubtedly results from social circumstances that predispose to recurrent respiratory tract infections. However, within this population, HTLV-1 infection was associated with multifocal bronchiectasis, increased morbidity, and a higher disease-specific mortality. These findings suggest that, in a setting of social deprivation, HTLV-1 infection both increases the risk of developing bronchiectasis and worsens its outcome. Although genetic and viral factors may contribute to this risk, the possibility that environmental factors are major determinants of the clinical expression of HTLV-1-associated disease warrants further study. The outcome of such work may have major health benefits for the Indigenous people of central Australia and for nearly 20 million [11] persons living with HTLV-1 in resource-poor endemic regions elsewhere.
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